MGTX Projected Dividend Yield
Ord/MeiraGTx Holdings PLC ( NASDAQ : MGTX )Meiragtx Holdings is a clinical stage gene therapy company. Co. focuses on: ocular diseases, including both inherited retinal diseases as well as degenerative ocular diseases; neurodegenerative diseases; and severe forms of xerostomia. Co.'s ophthalmology programs include Botaretigene Sparoparvovec for the treatment of X-linked retinitis pigmentosa associated with mutations in the retinitis pigmentosa GTPase regulator gene, which is an inherited retinal diseases which represent the genetic cause of blindness. Co.'s salivary gland programs include AAV-hAQP1 for the treatment of radiation-induced grade 2/3 xerostomia, which is a side effect of radiation treatment for head and neck cancer. 20 YEAR PERFORMANCE RESULTS |
MGTX Dividend History Detail MGTX Dividend News MGTX Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |